STOCK TITAN
  1. Home
  2. Sec-filings
  3. ARCT
  4. [Form 4] Arcturus Therapeutics Holdings Inc. Insider Trading Activity

Board member at Arcturus (NASDAQ: ARCT) receives 15,000 stock options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Arcturus Therapeutics Holdings Inc. director Magda Marquet received a grant of stock options covering 15,000 shares of common stock, with an exercise price of $7.30 per share and an expiration date of June 5, 2036. The options vest monthly over one year from the grant date and represent her 2026 annual grant as a member of the company’s Board of Directors.

Positive

  • None.

Negative

  • None.
Insider Marquet Magda
Role null
Type Security Shares Price Value
Grant/Award Stock option (right to buy) 15,000 $0.00 --
Holdings After Transaction: Stock option (right to buy) — 15,000 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Option grant size 15,000 options Stock option (right to buy) granted to director Magda Marquet
Exercise price $7.30 per share Conversion or exercise price of the stock options
Expiration date June 5, 2036 Option expiration for director’s 2026 annual grant
Underlying shares 15,000 shares Shares of Arcturus common stock underlying the option grant
Stock option (right to buy) financial
"security_title: Stock option (right to buy)"
Common Stock financial
"underlying_security_title: Common Stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
Board of Directors financial
"member of the Board of Directors of the Issuer"
The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.
vest monthly financial
"Shares underlying the option vest monthly over a one year period"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Marquet Magda
(Last)(First)(Middle)
C/O ARCTURUS THERAPEUTICS HOLDINGS INC.
10285 SCIENCE CENTER DRIVE
(Street)
SAN DIEGO CALIFORNIA 92121
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Arcturus Therapeutics Holdings Inc. [ ARCT ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock option (right to buy)(1)$7.306/05/2026A15,000 (1)06/05/2036Common Stock15,000$0.0015,000D
Explanation of Responses:
1. Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2026 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.
/s/ Ilan Katz, attorney-in-fact06/15/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Magda Marquet receive in this Arcturus (ARCT) Form 4 filing?

Magda Marquet received a grant of stock options for 15,000 shares of Arcturus common stock. These options are part of her 2026 annual compensation as a member of the company’s Board of Directors and are recorded as a derivative security grant.

What is the exercise price of Magda Marquet’s new Arcturus (ARCT) stock options?

The stock options granted to Magda Marquet have an exercise price of $7.30 per share. This means she can purchase Arcturus common shares at $7.30 once the options vest, subject to the terms and expiry in the grant agreement.

How many Arcturus (ARCT) shares are covered by Magda Marquet’s option grant?

The option grant covers 15,000 underlying shares of Arcturus common stock. All 15,000 options were granted on the same date and are directly owned, with the total option position following the transaction reported as 15,000 derivative securities.

What is the vesting schedule for Magda Marquet’s Arcturus (ARCT) options?

The options vest monthly over one year starting from the grant date. This schedule gradually makes portions of the 15,000 options exercisable each month, reflecting ongoing service on Arcturus’s Board of Directors during the 2026 grant period.

When do Magda Marquet’s Arcturus (ARCT) stock options expire?

Magda Marquet’s stock options expire on June 5, 2036. She may exercise vested options at $7.30 per share any time before this expiration date, subject to the company’s equity plan terms and any applicable insider trading restrictions.